Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingqi Daozhi Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by the Shanghai Mental Health Center for the treatment of antipsychotic-induced constipation, particularly in patients with schizophrenia exhibiting a 'qi stagnation' pattern. The decoction is a multi-herb combination consisting of *Cistanche deserticola* (30 g), *Magnolia officinalis* (15 g), *Raphanus sativus* seed (15 g), and *Areca catechu* pericarp (10 g). It is formulated as oral granules. The formula is designed to promote gastrointestinal motility and resolve abdominal discomfort by addressing the TCM diagnostic pattern of stagnation. It is currently being evaluated in a Phase 1/2 randomized, double-blind, placebo-controlled exploratory trial to assess its efficacy in improving complete spontaneous bowel movements and constipation-related quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xingqi Daozhi Decoction.